sing an antiparasitic drug to enhance Hepatitis vaccinatio

Phase 2

Completed

• Conditions: Chronic renal failure.; Chronic kidney disease

• Registration Number: IRCT201306296388N5
• Lead Sponsor: Vice chancellor for research, Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

(being negative for hepatitis B antibody; to suffer from chronic renal failure without any prior history for hepatitis B vaccination)
Exclusion criteria: (to have antibody titer more than 10 international units or having a history of hepatitis B vaccination; having clues for any autoimmune or other systemic disease; having a positive history for immunosuppressive drugs consumption in the last 6 months)

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HBs antigen titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HBs antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HBc antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HCV antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HIV antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.